The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

The co-creator and screenwriter of the 'Back to the Future' trilogy has been very outspoken about the possibility of a fourth ...

A screenwriter for Back to the Future issued a savage response after being questioned on a possible fourth sequel. The sci-fi ...

Conductor Daniel Barenboim says he has been diagnosed with Parkinson’s disease. The 82-year-old issued a statement Thursday ...

Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the ...

The writer of Back To The Future, Bob Gale, has given a blunt reaction to the idea of there ever being a fourth film.

Gain's lead program in Parkinson's disease has been awarded funding support from The Michael J. Fox Foundation for ...

Newel Health has been granted EU medical device certification for its virtual reality-based digital therapeutic (DTx) for chronic pain, clearing the way for a launch in Europe.

The Google cofounder has donated more than $1.5 billion to Parkinson’s research. Now, as he takes on autism, he’s also ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

Birmingham, England benefit concert Back to the Beginning also features Metallica, Slayer, Pantera, Gojira and more on the ...

Taryn Robertson, a professor at Randolph College, is currently fundraising and training to run a marathon for her father who ...